Junlin Yu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Junlin Yu has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
Chan Xiao
Zhibing Sun Xiaogan Hospital, Wuhan University of Science and Technology
1 shared publicationChaohua Hu
Zhibing Sun Xiaogan Hospital, Wuhan University of Science and Technology
1 shared publication- Han Feng
Department of Oncology, The First Affiliated Hospital of Zhengzhou University, No 1. Jianshe Road, Erqi District, Zhengzhou, Henan 450052 China
1 shared publication Haoyuan Shen
Zhibing Sun Xiaogan Hospital, Wuhan University of Science and Technology
1 shared publication- Kang Cui
Department of Oncology, The First Affiliated Hospital of Zhengzhou University, No 1. Jianshe Road, Erqi District, Zhengzhou, Henan 450052 China
1 shared publication - Qing-Xia Fan
Department of Oncology, The First Affiliated Hospital of Zhengzhou University, No 1. Jianshe Road, Erqi District, Zhengzhou, Henan 450052 China
1 shared publication
Latest Publications
- Open Access
- 16 January 2026
- Published by Springer Nature in Research Square
Immune cell score model is a new tumor marker for predicting prognosis and selecting therapeutic drugs in thyroid cancer
Immune cells are widely distributed in the microenvironment of thyroid cancer, which promote or inhibit tumor development at different stages of tumorigenesis. The immune microenvironment of tumors may play an important role in tumor development. The number and function of immune cells infiltrated in different compartments of the tumor tissue affect the prognosis of tumor patients. The characteristics and clinical value of the immune microenvironment of thyroid cancer are unknown. In this study, the characteristic of the immune microenvironment of thyroid cancer was analyzed. The immune cell score was used to construct a risk model, and further investigated relationship between the model and the prognosis and drug sensitivity of thyroid cancer. The correlation between immune cells and immune genes was studied in the model. The model predicts the prognosis of thyroid cancer, identifies high-risk groups of thyroid cancer, and screens dominant populations benefiting from immunotherapy. It provides reference for prognosis evaluation and treatment strategy of thyroid cancer.
- 16 January 2026
- Published by Springer Nature in Research Square
Open AccessImmune cell score model is a new tumor marker for predicting prognosis and selecting therapeutic drugs in thyroid cancer
Immune cells are widely distributed in the microenvironment of thyroid cancer, which promote or inhibit tumor development at different stages of tumorigenesis. The immune microenvironment of tumors may play an important role in tumor development. The number and function of immune cells infiltrated in different compartments of the tumor tissue affect the prognosis of tumor patients. The characteristics and clinical value of the immune microenvironment of thyroid cancer are unknown. In this study, the characteristic of the immune microenvironment of thyroid cancer was analyzed. The immune cell score was used to construct a risk model, and further investigated relationship between the model and the prognosis and drug sensitivity of thyroid cancer. The correlation between immune cells and immune genes was studied in the model. The model predicts the prognosis of thyroid cancer, identifies high-risk groups of thyroid cancer, and screens dominant populations benefiting from immunotherapy. It provides reference for prognosis evaluation and treatment strategy of thyroid cancer.
- Open Access
- 30 July 2019
- Published by Springer Nature in Cancer Cell International
- Vol. 19 (1) , 1-10
Long noncoding RNA DIO3OS interacts with miR-122 to promote proliferation and invasion of pancreatic cancer cells through upregulating ALDOA
Long noncoding RNA (lncRNA) has been implicated in numerous tumors, including pancreatic cancer (PC). However, the precise cellular roles and molecular mechanisms of lncRNA DIO3OS on PC development remains to be fully clarified. We performed the meta-analysis on PC samples and non-tumor samples retrieved from the TCGA database, and measured the levels of DIO3OS in PC cell lines and a normal pancreatic duct epithelial cell line HPDE6-C7. Cell proliferation was evaluated via CCK-8 assay. Cell invasion in vitro was investigated by transwell assay. The RNA immunoprecipitation assay and luciferase reporter assay was utilized to confirm the putative miR-122-binding site in DIO3OS. The effects of DIO3OS on PC progression were tested using in vivo subcutaneous xenografts. Our results showed that DIO3OS was highly expressed in human PC tissues and PC cell lines. DIO3OS exhibited oncogenic properties in stimulating PC cell proliferation and invasion in vitro and promoting cancer growth in vivo. Through online predictive tools and functional experiments, we found that DIO3OS could bind directly to microRNA-122 (miR-122) and inhibited its expression, which functioned as a tumor suppressor in PC cells. We also verified that ALDOA was the direct target of miR-122, and the tumor suppressive effects caused by DIO3OS knockdown or miR-122 overexpression could be rescued by re-expression of ALDOA in PC cells. Overall, our study suggested that lncRNA DIO3OS promotes PC cell growth and invasion by competing for miR-122 to modulate the expression of ALDOA. These findings yield a better understanding of the potential mechanisms by which gain of DIO3OS expression accelerates PC progression.
- 30 July 2019
- Published by Springer Nature in Cancer Cell International
- Vol. 19 (1) , 1-10
Open AccessLong noncoding RNA DIO3OS interacts with miR-122 to promote proliferation and invasion of pancreatic cancer cells through upregulating ALDOA
Long noncoding RNA (lncRNA) has been implicated in numerous tumors, including pancreatic cancer (PC). However, the precise cellular roles and molecular mechanisms of lncRNA DIO3OS on PC development remains to be fully clarified. We performed the meta-analysis on PC samples and non-tumor samples retrieved from the TCGA database, and measured the levels of DIO3OS in PC cell lines and a normal pancreatic duct epithelial cell line HPDE6-C7. Cell proliferation was evaluated via CCK-8 assay. Cell invasion in vitro was investigated by transwell assay. The RNA immunoprecipitation assay and luciferase reporter assay was utilized to confirm the putative miR-122-binding site in DIO3OS. The effects of DIO3OS on PC progression were tested using in vivo subcutaneous xenografts. Our results showed that DIO3OS was highly expressed in human PC tissues and PC cell lines. DIO3OS exhibited oncogenic properties in stimulating PC cell proliferation and invasion in vitro and promoting cancer growth in vivo. Through online predictive tools and functional experiments, we found that DIO3OS could bind directly to microRNA-122 (miR-122) and inhibited its expression, which functioned as a tumor suppressor in PC cells. We also verified that ALDOA was the direct target of miR-122, and the tumor suppressive effects caused by DIO3OS knockdown or miR-122 overexpression could be rescued by re-expression of ALDOA in PC cells. Overall, our study suggested that lncRNA DIO3OS promotes PC cell growth and invasion by competing for miR-122 to modulate the expression of ALDOA. These findings yield a better understanding of the potential mechanisms by which gain of DIO3OS expression accelerates PC progression.